BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Stock analysts at Jefferies Group reduced their FY2018 earnings per share estimates for shares of BioCryst Pharmaceuticals in a report issued on Wednesday. Jefferies Group analyst M. Raycroft now anticipates that the biotechnology company will post earnings of ($0.62) per share for the year, down from their previous estimate of ($0.58). Jefferies Group currently has a “Buy” rating and a $7.00 target price on the stock. Jefferies Group also issued estimates for BioCryst Pharmaceuticals’ FY2019 earnings at ($0.69) EPS, FY2020 earnings at ($0.58) EPS and FY2021 earnings at ($0.34) EPS.

Several other research firms have also weighed in on BCRX. Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. Needham & Company LLC restated a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Friday, May 19th. Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Sunday, May 28th. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, ValuEngine lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 3rd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $9.13.

WARNING: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/08/jefferies-group-analysts-lower-earnings-estimates-for-biocryst-pharmaceuticals-inc-bcrx.html.

Shares of BioCryst Pharmaceuticals (NASDAQ BCRX) traded down 2.35% during mid-day trading on Friday, reaching $5.83. 1,501,870 shares of the company’s stock traded hands. BioCryst Pharmaceuticals has a 12-month low of $3.75 and a 12-month high of $9.25. The company’s market cap is $468.90 million. The firm has a 50-day moving average of $4.83 and a 200 day moving average of $6.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $5.79 million. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The business’s quarterly revenue was down 35.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.22) EPS.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 19.9% in the second quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after acquiring an additional 996,052 shares during the period. RA Capital Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 47.9% in the second quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock valued at $28,702,000 after acquiring an additional 1,672,447 shares during the period. State Street Corp boosted its position in shares of BioCryst Pharmaceuticals by 72.0% in the second quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock valued at $21,736,000 after acquiring an additional 1,636,909 shares during the period. FMR LLC boosted its position in shares of BioCryst Pharmaceuticals by 114.5% in the second quarter. FMR LLC now owns 3,124,676 shares of the biotechnology company’s stock valued at $17,373,000 after acquiring an additional 1,667,791 shares during the period. Finally, Jennison Associates LLC boosted its position in shares of BioCryst Pharmaceuticals by 12.8% in the second quarter. Jennison Associates LLC now owns 2,080,818 shares of the biotechnology company’s stock valued at $11,569,000 after acquiring an additional 236,182 shares during the period. Institutional investors own 86.23% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.